Pharmaceutical economics / William S. Comanor and Stuart O. Schweitzer

Von:

Comanor, William S, 1937- [aut]

Mitwirkende(r):

Resource type: Ressourcentyp: Buch (Online)Buch (Online)Sprache: Englisch Reihen: Elgar research reviews in economics | Edward Elgar E-Book ArchiveVerlag: Cheltenham : Edward Elgar Pub. Ltd, 2013Beschreibung: 1 Online-Ressource (1 v) ; cmISBN:

9781784710446

Schlagwörter:

Andere physische Formen: Erscheint auch als: Pharmaceutical economics. Druck-Ausgabe. Cheltenham [u.a.] : Elgar, 2013. XXXIII, 739 S.DDC-Klassifikation:

338.476151 23

LOC-Klassifikation:

HD9665.5

DOI: DOI: 10.4337/9781784710446Online-Ressourcen:

Zusammenfassung: Pharmaceutical Economics begins with an investigation of the structure of the industry and its three main components: the research firms which produce innovative products; the generic drug industry and its expanding role; and the biotech industry, which is regarded as the future for pharmaceuticals. Further sections discuss topics including demand and incentives, pricing and regulation. Professor Comanor and Professor Schweitzer have selected the most significant articles by leading academics, in order to offer a blend of standard economic interpretations of pharmaceutical policy and important new topics including biosimilars, insurance coverage for pharmaceuticals, price-fixing and direct-to-consumer advertising. An authoritative new introduction by the editors provides an insightful guide to these important topicsZusammenfassung: Bernard Munos (2009), 'Lessons from 60 Years of Pharmaceutical Innovation', Nature Reviews/Drug Discovery, 8, December, 959-68 -- Richard E. Caves, Michael D. Whinston and Mark A. Hurwitz (1991), 'Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry', Brookings Papers on Economic Activity. Microeconomics 1991, 1-48, 64-66 -- Henry Grabowski (2007), 'Competition between Generic and Branded Drugs', in Frank A. Sloan and Chee-Ruey Hseih (eds), Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, Chapter 8, Cambridge, UK: Cambridge University Press, 153-73, notes, references -- Fiona M. Scott Morton (1999), 'Entry Decisions in the Generic Pharmaceutical Industry', RAND Journal of Economics, 30 (3), Autumn, 421-40 -- Richard G. Frank and David S. Salkever (1997), 'Generic Entry and the Pricing of Pharmaceuticals', Journal of Economics and Management Strategy, 6 (1), Spring, 75-90 -- Steven Kozlowski, Janet Woodcock, Karen Midthun and Rachel Behrman Sherman (2011), 'Developing the Nation's Biosimilars Program', New England Journal of Medicine, 365 (5), August, 385-88 -- Scott Gottlieb (2008), 'Biosimilars: Policy, Clinical, and Regulatory Considerations', American Journal of Health-System Pharmacy, 65 (14 Supplement 6), July 15, S2-S8 -- Willard G. Manning, Joseph P. Newhouse, Naihua Duan, Emmett B. Keeler, Arleen Leibowitz and M. Susan Marquis (1987), 'Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment', American Economic Review, 77 (3), June, 251-77 -- Frank R. Lichtenberg and Shawn X. Sun (2007), 'The Impact of Medicare Part D on Prescription Drug Use by the Elderly', Health Affairs, 26 (6), November, 1735-44 -- Meredith B. Rosenthal, Ernst R. Berndt, Julie M. Donohue, Arnold M. Epstein and Richard G. Frank (2003), Demand Effects of Recent Changes in Prescription Drug Promotion, Report of the Henry J. Kaiser Family Foundation #6085, June, 1-33 -- Davina C. Ling, Ernst R. Berndt and Margaret K. Kyle (2002), 'Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales', Journal of Law and Economics, XLV, October, 691-723 -- Michele M. Spence, Stephanie S. Teleki, T. Craig Cheetham, Stuart O. Schweitzer and Mirta Millares (2005), 'Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing', Medical Care Research and Review, 62 (5), October, 544-59 -- Joel W. Hay (2004), 'Evaluation and Review of Pharmacoeconomic Models', Expert Opinion in Pharmacotherapy, 5 (9), September, 1-14 [1867-80] -- Ernst R. Berndt (2002), 'Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price', Journal of Economic Perspectives, 16 (4), Fall, 45-66 -- Z. John Lu and William S. Comanor (1998), 'Strategic Pricing of New Pharmaceuticals', Review of Economics and Statistics, 80 (1), February, 108-18 -- Jayanta Bhattacharya and William B. Vogt (2003), 'A Simple Model of Pharmaceutical Price Dynamics', Journal of Law and Economics, XLVI (2), October, 599-626 -- Stuart O. Schweitzer and William S. Comanor (2011), 'Prices of Pharmaceuticals in Poor Countries are Much Lower than in Wealthy Countries', Health Affairs, 30 (8), August, 1553-61 -- Patricia M. Danzon and Li-Wei Chao (2000), 'Cross-national Price Differences for Pharmaceuticals: How Large, and Why?', Journal of Health Economics, 19 (2), March, 159-95 -- Daniel Carpenter and Gisela Sin (2007), 'Policy Tragedy and the Emergence of Regulation: The Food, Drug, and Cosmetic Act of 1938', Studies in American Political Development, 21 (2), Fall, 149-80Zusammenfassung: Ernst R. Berndt, Robert S. Pindyck and Pierre Azoulay (2003), 'Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs', Journal of Industrial Economics, LI (2), June, 243-70 -- David Granlund (2010), 'Price and Welfare Effects of Pharmaceutical Substitution Reform', Journal of Health Economics, 29 (6), December, 856-65 -- Adrian Towse (2007), 'If It Ain't Broke, Don't Price Fix It: The OFT and the PPRS', Health Economics, 16 (7), July, 653-65 -- Stuart O. Schweitzer (2007), 'The Timing of Drug Approvals in the United States and Abroad', in Pharmaceutical Economics and Policy, Second Edition, Chapter 9, New York, NY: Oxford University Press, Inc., 191-206Zusammenfassung: IMS Institute for Healthcare Informatics (2011). The Use of Medicines in the United States: Review of 2010, April. -- IMS Institute for Healthcare Informatics (2012). The Global Use of Medicines: Outlook Through 2016, July. -- Intriligator, M. (1996). Drug Evaluations: Type I vs Type II Errors. Research Program in Pharmaceutical Economics and Policy, UCLA. May. -- Karki, L. (2005). Review of FDA Law Related to Pharmaceuticals: The Hatch-Waxman Act, Regulatory Amendments and Implications for Drug Patent Enforcement, Journal of the Patent & Trademark Office Society. 87, 602-20. -- Kessler, D., Rose, J. L., Temple, R. J., Schapiro, R. and Griffen, J. P. (1994). Therapeutic-Class Wars - Drug Promotion in a Competitive Marketplace, New England Journal of Medicine, 331, 1350-53. -- Langenfeld, J. and Maness, R. (2003). The Cost of PBM 'Self-Dealing' Under A Medicare Prescription Drug Benefit, Unpublished Paper. -- Leffler, K. B. (1981). Persuasion or Information? The Economics of Prescription Drug Advertising, Journal of Law & Economics, 24(1), April, 45-74. -- Ma, Q. and Lu, A. Y. H. (2011). Pharmacogenetics, Pharmacogenomics, and Individualized Medicine, Pharmacological Reviews, 63(2), 437. -- Miller, H. I. (2000). To America's Health: A Proposal to Reform the Food and Drug Administration, Hoover Institution Press, Stanford, CA. -- Miller, R. D., Jr. and Frech, H. E. III (2004). Healthcare Matters: Pharmaceuticals, Obesity and the Quality of Life, American Enterprise Institute, 2-30. -- Peltzman, S. (1973). An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments, Journal of Political Economy, 81(5), 1049-91. -- Reiffen, D. E. and Ward, M. E. (2005). Generic Drug Industry Dynamics, Review of Economics and Statistics, 87, 37-49. -- Reinhart, U. (2001). Perspectives on the Pharmaceutical Industry, Health Affairs, 20(5), 136-49. -- Scherer, F. M. (2010). 'Pharmeceutical Innovation,' in Hall, B. and Rosenberg, N., eds, Handbook of the Economics of Technological Industry, North Holland, 552. -- Schwartzman, D. (1976). Innovation in the Pharmaceutical Industry, The Johns Hopkins University Press, Baltimore, MD. -- Schweitzer, S. O. (2007). Pharmaceutical Economics and Policy, 2nd edition, Oxford University Press, Oxford. -- Schweitzer, S. O. (2013). How the US Food and Drug Administration Can Solve the Prescription Drug Shortage Problem, American Journal of Public Health, Public Health Policy Briefs, e1-e5. -- Scott Morton, F. (2000). Barriers to Entry, Brand Advertising, and Generic Entry in the US Pharmaceutical Industry, International Journal of Industrial Organization, 18(7), 1085-104. -- Scriabine, A. (1999). 'The Role of Biotechnology in Drug Development,' in Landau, R. et al., eds, Pharmaceutical Innovation, Chemical Heritage Press, 271-97Zusammenfassung: Recommended readings (Machine generated): Blume-Kohout, M. E. and Sood, N. (2013). Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development, Journal of Public Economics, 97, 327-36. -- Bond, R. S. and Lean, D. F. (1979). Sales, Promotion, and Products Differentiation in Two Prescription Drug Markets, Staff Report to the FTC, 46. -- Boslaugh, S. (2008). Encyclopedia of Epidemiology, Sage Publications, Thousand Oaks, CA, p. 395. -- Carpenter, D. (2010). Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, Princeton University Press, Princeton, NJ. -- Carpenter, D. and Sin, G. (2007). Policy Tragedy and the Emergence of Regulation: The Food, Drug, and Cosmetic Act of 1938, Studies in American Political Development, 21(02), 149-80. -- Clarkson, K. (1977). Intangible Capital and Rates of Return: Effects of Research and Promotion on Profitability, American Enterprise Institute for Public Policy Research. -- Cockburn, I. M. (2004). The Changing Structure of the Pharmaceutical Industry, Health Affairs, 23(1), 10. -- Cockburn, I. M. and Henderson, R. (2001). Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research, Journal of Health Economics, 751, 1-25. -- Comanor, W. S. and Scherer, F. M. (2013). Mergers and Innovation in the Pharmaceutical Industry, Journal of Health Economics, 32, 106-13. -- Comanor, W. S. and Schweitzer, S. O. (2007). Determinants of Drug Prices and Expenditures, Managerial and Decision Economics, 28, 358-70. -- Danzon, P. M. and Furukawa, M. F. (2008). International Prices and Availability of Pharmaceuticals in 2005, Health Affairs, 27(1), 221-33. -- Danzon, P. M. and Pauly, M. (2002). Health Insurance and the Growth of Pharmaceutical Expenditures, Journal of Law and Economics, XLV, 587-613. -- Davis, M., Poisal, J., Chulis, G., Zarabozo, C. and Cooper, B. (1999). Prescription Drug Coverage, Utilization, and Spending Among Medicare Beneficiaries, Health Affairs, 18(1), 231-43. -- DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. (2003). The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics, 22(2), 151-85. -- Duggan, M. and Scott Morton, F. (2006). The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing, Quarterly Journal of Economics, 121(1), 1-29. -- Esposito, D. (2006). Copayments and the Demand for Perscription Drugs. Routledge, Abingdon, Oxon, UK and New York, NY. -- Fierce Biotech. (2013). The Biotech Market Share Report. Available at: http://www.fiercebiotech.com/special-reports/biotech-marketshare-report. -- Gellad, W. F., Schneeweiss, S., Brawarsky, P., Lipsitz, S. and Hass, J. (2008). What if the Federal Government Negotiated Pharmaceutical Prices for Seniors? An Estimate of National Savings, Journal of General Internal Medicine, 23(9), 1435-40. -- Grabowski, H. G. and Vernon, J. M. (1994). Returns to R&D on New Drug Introductions in the 1980s, Journal of Health Economics, 13(4), 383-406. -- Gray, A. and Manasse, H. R. (2012). Shortages of Medicines: A Complex Global Challenge, Bulletin of the World Health Organization, 90, 158-158AZusammenfassung: Sorrell v. IMS Health, Inc. (2011). 131 S. Ct. 2653, 2659, 180 L. Ed. 2d 544. -- Stafford, R. S. (2008). Regulating Off-Label Drug Use - Rethinking the Role of the FDA, New England Journal of Medicine, 358(14), 1427-29. -- United States Congress, Office of Technology Assessment (USOTA) (1993). Pharmaceutical R&D: Costs, Risks and Rewards. OTA-H-522. US Government Printing Office, Washington, D.C. -- United States Congressional Budget Office (CBO) (2005). Prices for Brand-Name Drugs Under Selected Federal Programs. US Government Printing Office, Washington, D.C. -- United States Congressional Budget Office (CBO) (2009). Pharmaceutical R&D and the Evolving Market for Prescription Drugs. US Government Printing Office, Washington, D.C. -- United States v. Caronia (2012). WL 5992141 (US Court of Appeals, 2d Cir., Dec. 3, 2012). -- United States, Statistical Abstract of the United States (Stat. Abs U.S.) (2011). US Government Printing Office, Washington, D.C. -- Weiss, D., Naik, P. and Weiss, R. (2009). The 'Big Pharma' Dilemma: Develop New Drugs or Promote Existing Ones? Nature Reviews/Drug Discovery, 8, 533. -- Wiecek, A. and Mikhail, A. (2006). European Regulatory Guidelines for Biosimilars, Nephrology Dialysis Transplantation, 21: Suppl 5, v17-v20. -- Patricia M. Danzon, Andrew Epstein and Sean Nicholson (2007), 'Mergers and Acquisitions in the Pharmaceutical and Biotech Industries', Managerial and Decision Economics, 28 (4-5), June-August, 307-28 -- Iain Cockburn and Rebecca Henderson (1994), 'Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery', Journal of Economics and Management Strategy, 3 (3), Fall, 481-519 -- William S. Comanor (2007), 'The Economics of Research and Development in the Pharmaceutical Industry', in Frank A. Sloan and Chee-Ruey Hsieh (eds), Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, Chapter 3, Cambridge, UK: Cambridge University Press, 54-72, notes, references -- Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski and Louis Lasagna (1991), 'Cost of Innovation in the Pharmaceutical Industry', Journal of Health Economics, 10 (2), July, 107-42 -- Rebecca Henderson and Iain Cockburn (1996), 'Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery', RAND Journal of Economics, 27 (1), Spring, 32-59 -- F.M. Scherer (2001), 'The Link between Gross Profitability and Pharmaceutical R&D Spending', Health Affairs, 20 (5), September, 216-20 -- Patricia M. Danzon, Sean Nicholson and Nuno Sousa Pereira (2005), 'Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances', Journal of Health Economics, 24 (2), March, 317-39 -- Henry Grabowski, John Vernon and Joseph A. DiMasi (2002), 'Returns on Research and Development for 1990s New Drug Introductions', PharmacoEconomics, 20 (3 Supplement), December, 11-29 -- Mark Duggan and Fiona Scott Morton (2010), 'The Effect of Medicare Part D on Pharmaceutical Prices and Utilization', American Economic Review, 100 (1), March, 590-607 -- Frank R. Lichtenberg (2003), 'Pharmaceutical Innovation, Mortality Reduction, and Economic Growth', in Kevin M. Murphy and Robert H. Topel (eds), Measuring the Gains from Medical Research: An Economic Approach, Chapter 3, Chicago, IL: University of Chicago Press, 74-109PPN: PPN: 1023447622Package identifier: Produktsigel: ZDB-1-EWE | ZDB-77-EEC | ZDB-77-ESH

Exemplare ( 0 )

Dieser Titel hat keine Exemplare